These are Fidia Pharma USA Inc's four leading principles.
Through our employees and research, we develop and deliver value added solutions to healthcare challenges.
Abano Terme, Italy, April 25, 2018 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces that new data will be presented at the Osteoarthritis Research Society International (OARSI) World Congress Meeting in Liverpool, U.K., April 26-29.
Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results from a phase II trial evaluating efficacy and tolerability of Oncofid®P-B, an innovative Paclitaxel-Hyaluronan Bioconjugate targeted to cancer cells, in patients with primary or recurrent Ta G1-G2 papillary bladder cancer.
Florham Park, NJ, March 9, 2018 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA) based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces new data will be presented at the Annual Meeting of the Orthopaedic Research Society (ORS) in New Orleans, LA, March 10th-13th, 2018.
Diagnosed with OSTEOARTHRITIS (OA) of the knee?
You may be eligible to participate in a clinical trial
Learn More
